• Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Nymox Pharmaceutical Corp

+ Add to Watchlist

NYMX:US

0.5500 USD 0.0500 8.33%

As of 17:10:00 ET on 11/28/2014.

Snapshot for Nymox Pharmaceutical Corp (NYMX)

Open: 0.6400 Day's Range: 0.5400 - 0.6400 Volume: 486,865
Previous Close: 0.6000 52wk Range: 0.4500 - 7.1000 1-Yr Rtn: -92.14%

Stock Chart for NYMX

No chart data available.
  • NYMX:US 0.5500
  • 1D
  • 1M
  • 1Y
0.6000
Interactive NYMX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NYMX

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.1500
Est. EPS (USD) (12/2014) -
Est. PEG Ratio -
Market Cap (M USD) 19.28
Shares Outstanding (M) 35.05
30 Day Average Volume 1,315,935
Price/Book (mrq) -
Price/Sale (ttm) 7.6469
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NYMX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NYMX

Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is engaged in therapeutics in development for enlarged prostate (BPH), E. coli, Alzheimer's disease and other indications and diagnostics for tobacco exposure, Alzheimer's disease and other conditions.

Paul AverbackChairman/President/CEO/FounderAndre MonetteChief Financial Officer
Jack GemmellCIO/General CounselBrian DoyleSenior Mgr:Global Sales & Mktg
More Company Profile & Key Executives for NYMX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil